EPOPROSTENOL for Pulmonary veno-occlusive disease: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 20 adverse event reports in the FDA FAERS database where EPOPROSTENOL was used for Pulmonary veno-occlusive disease.
Most Reported Side Effects for EPOPROSTENOL
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Dyspnoea | 2,744 | 20.6% | 674 | 2,311 |
| Headache | 2,425 | 18.2% | 338 | 1,814 |
| Diarrhoea | 2,310 | 17.3% | 398 | 1,784 |
| Nausea | 2,016 | 15.1% | 345 | 1,606 |
| Pain in jaw | 1,928 | 14.5% | 302 | 1,484 |
| Death | 1,362 | 10.2% | 1,362 | 890 |
| Flushing | 1,256 | 9.4% | 143 | 930 |
| Fatigue | 1,133 | 8.5% | 191 | 875 |
| Hospitalisation | 1,078 | 8.1% | 234 | 1,074 |
| Vomiting | 1,068 | 8.0% | 200 | 891 |
| Pulmonary arterial hypertension | 1,055 | 7.9% | 475 | 864 |
| Malaise | 980 | 7.4% | 192 | 805 |
| Dyspnoea exertional | 938 | 7.0% | 179 | 822 |
| Fluid retention | 929 | 7.0% | 280 | 877 |
| Pain in extremity | 910 | 6.8% | 111 | 661 |
Other Indications for EPOPROSTENOL
Pulmonary arterial hypertension (8,508)
Pulmonary hypertension (2,486)
Product used for unknown indication (1,625)
Cor pulmonale chronic (239)
Portopulmonary hypertension (52)
Acute respiratory distress syndrome (42)
Covid-19 (26)
Right ventricular failure (25)
Dyspnoea (19)
Raynaud's phenomenon (19)
Other Drugs Used for Pulmonary veno-occlusive disease
TREPROSTINIL (22)
AMBRISENTAN (17)
SILDENAFIL (14)
IMATINIB (13)
MACITENTAN (11)
DEFIBROTIDE (8)
BOSENTAN (5)
SELEXIPAG (5)
TADALAFIL (5)